Abstract: A computing system receives location data from a computing device of a transport provider and based on the location data, monitors a location of the transport provider as the transport provider operates a vehicle to travel towards a service location of the service request. The system determines, based on monitoring the location of the transport provider, that the transport provider has not indicated at least one of a correct start location or a correct start time for fulfilling the service request. In response to determining that the transport provider has not indicated the at least one of the correct start location or the correct start time, the system uses a set of the location data received from the computing device of the transport provider to determine the at least one of the correct start location or the correct start time for fulfilling the service request.

Abstract: The present technology is directed to methods useful in treating cancer, slowing growth of a tumor, reversing growth of a tumor, slowing growth of a neoplasm, reversing growth of a neoplasm, slowing proliferation of a neoplasm, and/or reversing proliferation of a neoplasm, for cancers, tumors, and neoplasms harboring a constitutively active variant of one or both of KRAS or HRAS, where the constitutively active variant is a gain of function mutation, a duplication, or a gene amplification.

Abstract: A computing system receives location data from a computing device of a transport provider and based on the location data, monitors a location of the transport provider as the transport provider operates a vehicle to travel towards a service location of the service request. The system determines, based on monitoring the location of the transport provider, that the transport provider has not indicated at least one of a correct start location or a correct start time for fulfilling the service request. In response to determining that the transport provider has not indicated the at least one of the correct start location or the correct start time, the system uses a set of the location data received from the computing device of the transport provider to determine the at least one of the correct start location or the correct start time for fulfilling the service request.

Abstract: Described herein are novel devices and methods for the optical detection of oligonucleotide binding events for diagnostic, point-of-care, drug screening, and theranostic applications, for example, a robust and customizable system to detect specific DNA and RNA oligonucleotides using a carbon nanotube optical signal.

Abstract: Described herein are suspensions of helical polycarbodiimide polymers that ‘cloak’ nanotubes, thereby effecting control over nanotube emission, providing a new mechanism of environmental responsivity, and enabling precise control over sub-cellular localization. The helical polycarbodiimide polymers described herein are water soluble, easily modifiable, and have unique architectures that facilitate their application in radiopharmaceutical delivery and imaging methods, in therapeutics and therapeutic delivery methods, and their use as sensors—both in conjunction with carbon nanotubes, and without nanotubes.

Abstract: A computer system can communicate with a mobile device of a service provider to receive location data. Additionally, the computer system can monitor, from the location data, a location of the mobile device over a duration that follows the service provider being assigned to a service request. Based on monitoring the location data, the computer system can determine whether the service provider has failed to correctly indicate when a transport service for the service request began. Moreover, the computer system can cause a service application running on the mobile device to prompt the service provider to enter input to identify a start location where the transport service began, in response to the computer system determining that the service provider has not correctly indicated when the transport service begun.

Abstract: A computer system can communicate with a mobile device of a service provider to receive location data. Additionally, the computer system can monitor, from the location data, a location of the mobile device over a duration that follows the service provider being assigned to a service request. Based on monitoring the location data, the computer system can determine whether the service provider has failed to correctly indicate when a transport service for the service request began. Moreover, the computer system can cause a service application running on the mobile device to prompt the service provider to enter input to identify a start location where the transport service began, in response to the computer system determining that the service provider has not correctly indicated when the transport service begun.

Abstract: Described herein are suspensions of helical polycarbodiimide polymers that ‘cloak’ nanotubes, thereby effecting control over nanotube emission, providing a new mechanism of environmental responsivity, and enabling precise control over sub-cellular localization. The helical polycarbodiimide polymers described herein are water soluble, easily modifiable, and have unique architectures that facilitate their application in radiopharmaceutical delivery and imaging methods, in therapeutics and therapeutic delivery methods, and their use as sensors—both in conjunction with carbon nanotubes, and without nanotubes.

Abstract: A system for programmatically determining location information in connection with a transport service is disclosed. A driver can operate a driver device and can be assigned to provide a transport service for a user. Based on the current location of the driver device with respect to the pickup location for the user, and based on when the driver provides input indicating that the transport service has begun, the system can identify a previous location of the driver device as a start location of the transport service.

Abstract: Described herein are novel devices and methods for the optical detection of oligonucleotide binding events for diagnostic, point-of-care, drug screening, and theranostic applications, for example, a robust and customizable system to detect specific DNA and RNA oligonucleotides using a carbon nanotube optical signal.

Abstract: A system for programmatically determining location information in connection with a transport service is disclosed. A driver can operate a driver device and can be assigned to provide a transport service for a user. Based on the current location of the driver device with respect to the pickup location for the user, and based on when the driver provides input indicating that the transport service has begun, the system can identify a previous location of the driver device as a start location of the transport service.

Abstract: A system for programmatically determining location information in connection with a transport service is disclosed. A driver can operate a driver device and can be assigned to provide a transport service for a user. Based on the current location of the driver device with respect to the pickup location for the user, and based on when the driver provides input indicating that the transport service has begun, the system can identify a previous location of the driver device as a start location of the transport service.

Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.

Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.

Abstract: A system for programmatically determining location information in connection with a transport service is disclosed. A driver can operate a driver device and can be assigned to provide a transport service for a user. Based on the current location of the driver device with respect to the pickup location for the user, and based on when the driver provides input indicating that the transport service has begun, the system can identify a previous location of the driver device as a start location of the transport service.

Abstract: Disclosed are nordihydroguaiarctic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.

Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.

Abstract: Disclosed are nordihydroguaiaretic acid derivative compounds including various end groups bonded by a carbon atom or heteroatom though a side chain bonded to the respective hydroxy residue O groups by an ether bond or a carbamate bond, pharmaceutical compositions, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, a metabolic disease, such as diabetes, a vascular disease, such as hypertension and macular degeneration, or a proliferative disease, such as diverse types of cancers.

Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.

Abstract: The present invention relates to nordihydroguaiaretic acid derivative compounds, namely, butane bridge modified nordihydroguaiaretic acid (NDGA) compounds and butane bridge modified tetra-O-substituted NDGA compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them and kits including them for the treatment of diseases and disorders, in particular, diseases resulting from or associated with a virus infection, such as HIV infection, HPV infection, or HSV infection, an inflammatory disease, such as various types of arthritis and inflammatory bowel diseases, metabolic diseases, such as diabetes and hypertension, or a proliferative disease, such as diverse types of cancers.